MnTBAP Porphyrin Reverses Sepsis-Induced Microglial Alterations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are ineffective in addressing the immediate and long-term consequences of sepsis, particularly in preventing or alleviating brain dysfunction and cognitive impairment associated with sepsis-induced microglial cell alterations, which can lead to significant morbidity and mortality.
Innovation Solution
Administration of the superoxide dismutase mimetic compound MnTBAP, a nitroso-redox stress scavenger, to reduce oxidative and nitrosative stress in microglial cells, thereby reversing sepsis-induced microglial alterations and improving cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sepsis treatments (antibiotics, intravenous fluids) are administered, then immediate life-threatening organ dysfunction is addressed, but long-term cognitive impairment and brain dysfunction caused by microglial cell alterations are not prevented or alleviated
Solution Approach 1:
The patent applies preliminary action by administering the MnTBAP compound during the acute sepsis phase (within 48 hours of onset) to prevent microglial cell alterations before they can cause long-term cognitive impairment. This early intervention reverses microglial dysfunction and prevents the development of post-sepsis cognitive deficits, addressing both immediate survival and long-term neurological outcomes simultaneously
2Ease of operation
If no specific therapy is provided, then treatment simplicity is maintained, but microglial cell alterations lead to persistent neuro-inflammation and cognitive impairment
Solution Approach 1:
The patent introduces MnTBAP as an intermediary substance that mediates between the harmful oxidative stress environment and microglial cells. The compound acts as a superoxide dismutase mimetic and nitroso-redox stress scavenger, neutralizing reactive oxygen and nitrogen species to prevent microglial activation and subsequent neuro-inflammation, thereby protecting cognitive function without complicating the treatment regimen
3Loss of time
If sepsis is allowed to resolve naturally, then acute phase management is simplified, but microglial cells enter a primed state contributing to neurodegenerative disease pathogenesis
Solution Approach 1:
The patent applies preliminary anti-action by administering MnTBAP to counteract the priming effect on microglial cells during the acute sepsis phase. This prevents the epigenetic and immunological changes that would otherwise lead to persistent neuro-inflammation and contribute to neurodegenerative disease pathogenesis, thereby protecting long-term neurological health while allowing acute phase resolution
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MnTBAP effectively reduces mortality and improves long-term cognitive performance by reversing microglial dysfunction and oxidative stress, providing a therapeutic benefit even after the sepsis episode has resolved.
Implementation Method 1
reduce oxidative and nitrosative stress in microglial cells
Implementation Method 2
reduce oxidative and nitrosative stress in microglial cells
Implementation Method 3
the superoxide dismutase mimetic compound MnTBAP
Data Source
AI summary
The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-pYP5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2-Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis-associated encephalopathy (SAE).